The cost-effectiveness of prenatal screening for spinal muscular atrophy

American Journal of Obstetrics and Gynecology

Volumn 202, Issue 3, 2010, Pages 253.e1-253.e7

  Little, Sarah E ^a   Janakiraman, Vanitha ^a   Kaimal, Anjali ^a   Musci, Thomas ^b   Ecker, Jeffrey ^a   Caughey, Aaron B ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b San Francisco Perinatal Associates   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cost effectiveness; decision analysis; prenatal screening; spinal muscular atrophy

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRENATAL SCREENING; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; SPINAL MUSCULAR ATROPHY;

EID: 77649134088     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2010.01.032     Document Type: Article

References (26)

1. Kostova F.V., Williams V.C., Keemskerk J., et al. Spinal muscular atrophy: classification, diagnosis, management, pathogenesis, and future research directions. J Child Neurol 22 (2007) 926-945
2. Committee on Genetics. ACOG committee opinion no 432. Spinal muscular atrophy. Obstet Gynecol 133 (2009) 1194-1196
3. National Institute for Neurologic Disorders and Stroke. NINDS spinal muscular atrophy information page. http://www.ninds.nih.gov/disorders/sma/sma.htm Accessed Nov. 11, 2009
4. Prior T. Carrier screening for spinal muscular atrophy. Genet Med 10 (2008) 840-842
5. Caughey A.B., Hopkins L.M., and Norton M.E. Chorionic villus sampling compared with amniocentesis and the difference in the rate of pregnancy loss. Obstet Gynecol 108 (2006) 612-616
6. Odibo A.O., Gray D.L., Dicke J.M., Stamilio D.M., Macones G.A., and Crane J.P. Revisiting the fetal loss rate after second-trimester genetic amniocentesis: a single center's 16-year experience. Obstet Gynecol 111 (2008) 589-595
7. Eddleman K.A., Malone F.D., Sullivan L., et al. Pregnancy loss rates after midtrimester amniocentesis. Obstet Gynecol 108 (2006) 1067-1072
8. Doyle N.M., and Gardner M.O. Prenatal cystic fibrosis screening in Mexican Americans: an economic analysis. Am J Obstet Gynecol 189 (2003) 769-774
9. National Center for Health Statistics. National Vital Statistics United States for 2003 (2003), Public Health Services, Hyattsville, MD
10. US Department of Labor, Bureau of Labor Statistics. Consumer price indices (2009), US Bureau of Labor Statistics, Washington, DC
11. Siegel J.E., Weinstein M.C., Russell R.B., and Gold M.R. Recommendation for reporting cost-effectiveness analysis. JAMA 276 (1996) 1339-1341
12. Seattle Children's Hospital Genetic Laboratories. http://www.seattlechildrens.org/healthcare-professionals/access-services /diagnostic-services/geneticslab/ Accessed Nov. 11, 2009
13. Harris R.A., Washington A.E., Nease Jr. R.F., and Kuppermann M. Cost utility of prenatal diagnosis and the risk-based threshold. Lancet 363 (2004) 276-282
14. Waitzman N.J., Romano P.S., and Scheffler R.M. Estimates of the economic costs of birth defects. Inquiry 31 (1994) 188-205
15. US Department of Labor, Bureau of Labor Statistics. Compensation indices (2009), US Bureau of Labor Statistics, Washington, DC
16. Wang C.H., Finkel R.S., Bertini E.S., et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol 22 (2007) 1027
17. Hardart M.K., Burns J.P., and Truog R.D. Respiratory support in spinal muscular atrophy type I: a survey of physician practices and attitudes. Pediatrics 110 (2002) e24
18. Sevick M.A., Kamlet M.S., Hoffman L.A., and Rawson I. Economic cost of home-based care for ventilator-assisted individuals. Chest 109 (1996) 1597-1606
19. Kuppermann M., Nease R.F., Learman L.A., Gates E., Blumberg B., and Washington A.E. Procedure-related miscarriages and Down syndrome-affected births: implications for prenatal testing based on women's preferences. Obstet Gynecol 96 (2000) 511-516
20. Bach J.R., Vega J., Majors J., and Friedman A. Spinal muscular atrophy type 1 quality of life. Am J Phys Med Rehabil 82 (2003) 137-142
21. Owens D.K. Interpretation of cost-effectiveness analyses. J Gen Intern Med 13 (1998) 716-717
22. Gold M.R., Siegel J.E., Russell L.B., and Weinstein M.C. Cost-effectiveness in health and medicine (1996), Oxford University Press, New York
23. Dosiou C., Sanders G.D., Araki S.S., and Crapo L.M. Screening pregnant women for autoimmune thyroid disease: a cost-effectiveness analysis. Eur J Endocrinol 158 (2008) 841-851
24. Vandenbussche F.P., De Jong-Potjer L.C., Stiggelbout A.M., Le Cessie S., and Keirse M.J. Differences in the valuation of birth outcomes among pregnant women, mothers, and obstetricians. Birth 26 (1999) 178-183
25. Radhakrishnan M., van Gool K., Hall J., Delatycki M., and Massie J. Economic evaluation of cystic fibrosis screening: a review of the literature. Health Policy 85 (2008) 133-147
26. Rowley P.T., Loader S., and Kaplan R.M. Prenatal screening for cystic fibrosis: an economic evaluation. Am J Hum Genet 63 (1998) 1160-1174